Fluxome A/S, Copenhagen, Denmark, has entered a strategic exclusivity agreement with research-based biotechnology company GlycaNova Norway AS. Fluxome gains the exclusive rights from GlycaNova to market and sell a beta-glucan product in the U.S. dietary supplement market.

The final product, Fluxome Beta Glucan, developed by GlycaNova, is a natural beta-glucan product manufactured by fermentation. The product has been subject to a number of clinical trials, which confirm its immune-enhancing effects in humans, according to the companies.

The unique production process enables Fluxome to supply a standardized product with a guaranteed content of completely intact beta-glucan.